-
Publication Venue For
-
Guidelines for goals of care discussions in patients with gynecologic cancer..
174:247-252.
2023
-
Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study..
174:213-223.
2023
-
Understanding the spectrum of malignant bowel obstructions in gynecologic cancers and the application of the Henry score..
174:114-120.
2023
-
The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study..
173:130-137.
2023
-
"You start feeling comfortable, you just start sharing:" A qualitative study of patient distress screening in Black and White patients with endometrial cancer..
168:166-175.
2023
-
Implementing guidelines for risk-stratified thromboprophylaxis among gynecologic oncology patients: A quality improvement initiative..
168:144-150.
2023
-
Molecular testing for endometrial cancer: An SGO clinical practice statement..
168:48-55.
2023
-
Routine SLN biopsy for endometrial intraepithelial neoplasia: A pragmatic approach or over-treatment?.
168:A2-A3.
2023
-
A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trial..
167:423-428.
2022
-
Cost-effectiveness of management strategies for patients with recurrent ovarian cancer and inoperable malignant bowel obstruction..
167:523-531.
2022
-
SGO and the elephant that is still in the room: Wellness, burnout and gynecologic oncology.
2022
-
What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer..
166:410-416.
2022
-
Immunotherapy toxicities: An SGO clinical practice statement..
166:25-35.
2022
-
Malnutrition as a risk factor for post-operative morbidity in gynecologic cancer: Analysis using a national surgical outcomes database..
165:309-316.
2022
-
The ProMisE of uniform care for endometrial cancer patients..
165:199-200.
2022
-
Reducing non-surgical readmissions on a gynecologic oncology service..
165:4-10.
2022
-
Distress screening in endometrial cancer leads to disparity in referral to support services..
164:622-627.
2022
-
Promoting timely goals of care conversations between gynecologic cancer patients at high-risk of death and their providers..
164:288-294.
2022
-
Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association..
164:195-201.
2022
-
Adherence to PARP inhibitor therapy among women with ovarian cancer..
163:262-268.
2021
-
Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer..
163:246-253.
2021
-
Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL)..
163:237-245.
2021
-
Obesity and altered angiogenic-related gene expression in endometrial cancer..
163:320-326.
2021
-
Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer..
163:50-56.
2021
-
Society of Gynecologic Oncology (SGO) 2021 meeting report: Scaling new heights with innovative cancer care..
163:5-10.
2021
-
The oncology care model and the future of alternative payment models: A gynecologic oncology perspective..
162:529-531.
2021
-
Use and outcomes of neoadjuvant chemotherapy for metastatic uterine cancer..
162:599-605.
2021
-
Cardiovascular medications and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada..
162:461-468.
2021
-
Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review..
162:482-495.
2021
-
The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens..
162:440-446.
2021
-
A quality improvement initiative to reduce venous thromboembolism on a gynecologic oncology service..
162:120-127.
2021
-
Chemotherapy discontinuation processes in a gynecologic oncology population..
161:508-511.
2021
-
Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC)..
161:382-388.
2021
-
Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I/II endometrioid endometrial cancer: To treat or not to treat?.
161:347-352.
2021
-
Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer..
161:496-501.
2021
-
Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study..
161:113-121.
2021
-
The presence of an endometrioid component does not alter the clinicopathologic profile or survival of patients with uterine serous cancer: A gynecologic oncology group (GOG/NRG) study of 934 women..
160:660-668.
2021
-
Genetically predicted circulating protein biomarkers and ovarian cancer risk..
160:506-513.
2021
-
Racial and ethnic disparities in palliative care utilization among gynecological cancer patients..
160:469-476.
2021
-
Standardization of lower extremity quantitative lymphedema measurements and associated patient-reported outcomes in gynecologic cancers..
160:625-632.
2021
-
Universal screening for Lynch syndrome in uterine cancer patients: A quality improvement initiative..
160:169-174.
2021
-
The ASTRO clinical practice guidelines in cervical cancer: Optimizing radiation therapy for improved outcomes..
159:607-610.
2020
-
Cost-effectiveness analysis comparing "PARP inhibitors-for-all" to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer..
159:483-490.
2020
-
Pathologic and clinical tumor size discordance in early-stage cervical cancer: Does it matter?.
159:354-358.
2020
-
Identifying the worst of the worst: HER2 positive early stage uterine papillary serous carcinoma..
159:1-2.
2020
-
Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival..
158:702-709.
2020
-
Risk of second primary cancers among survivors of gynecological cancers..
158:719-726.
2020
-
When to Operate, Hesitate and Reintegrate: Society of Gynecologic Oncology Surgical Considerations during the COVID-19 Pandemic..
158:236-243.
2020
-
Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis..
158:16-24.
2020
-
Cardiometabolic comorbidities and epithelial ovarian cancer risk among African-American women in the African-American Cancer Epidemiology Study (AACES)..
158:123-129.
2020
-
A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma..
157:585-592.
2020
-
Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: Is there a role for chemotherapy?.
156:568-574.
2020
-
Differential expression of immune related genes in high-grade ovarian serous carcinoma..
156:662-668.
2020
-
Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer..
156:530-534.
2020
-
Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment..
156:561-567.
2020
-
Society of gynecologic oncology future of physician payment reform task force: Lessons learned in developing and implementing surgical alternative payment models..
156:701-709.
2020
-
European society of medical oncology (ESMO) 2019 meeting report features practice changing data in gynecologic malignancies..
156:265-270.
2020
-
Off-study utilization of experimental therapies: Analysis of GOG249-eligible cohorts using real world data..
156:154-161.
2020
-
Place of death by region and urbanization among gynecologic cancer patients: 2006-2016..
155:98-104.
2019
-
Gender variation in Medicare utilization and payments in gynecologic oncology..
154:602-607.
2019
-
Clinicopathologic features and treatment in patients with early stage uterine clear cell carcinoma: A 16-year experience..
154:328-332.
2019
-
Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data..
154:441-448.
2019
-
Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies..
154:199-206.
2019
-
Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer..
153:555-561.
2019
-
A pilot study of lower extremity lymphedema, lower extremity function, and quality of life in women after minimally invasive endometrial cancer staging surgery..
153:399-404.
2019
-
Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy..
153:376-380.
2019
-
GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study..
153:335-342.
2019
-
Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women..
153:343-355.
2019
-
Impact of a documentation intervention on health-assessment metrics on an inpatient gynecologic oncology service..
153:385-390.
2019
-
The association between progesterone receptor expression and survival in women with adult granulosa cell tumors..
153:74-79.
2019
-
Health Services Research: Not just retrospective chart reviews..
152:437-438.
2019
-
Measuring cause-and-effect relationships without randomized clinical trials: Quasi-experimental methods for gynecologic oncology research..
152:533-539.
2019
-
Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy..
152:554-559.
2019
-
Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer..
152:445-451.
2019
-
Prognostic factors impacting survival in early stage uterine carcinosarcoma..
152:31-37.
2019
-
A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study..
151:422-427.
2018
-
Gender trends in gynecologic oncology authorship: Implications for the critical evaluation of gender distribution in academic rank and leadership positions..
151:542-546.
2018
-
Hysterectomy with sentinel lymph node biopsy in the setting of pre-operative diagnosis of endometrial intraepithelial neoplasia: A cost-effectiveness analysis..
151:506-512.
2018
-
Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study..
151:257-263.
2018
-
Benign hysterectomy performed by gynecologic oncologists: Is selection bias altering our ability to measure surgical quality?.
151:141-144.
2018
-
Histotype classification of ovarian carcinoma: A comparison of approaches..
151:53-60.
2018
-
Predicting non-home discharge in epithelial ovarian cancer patients: External validation of a predictive model..
151:129-133.
2018
-
A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254)..
150:247-252.
2018
-
A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer..
150:274-281.
2018
-
Cabozantinib in ovarian clear cell cancers: UnMET expectations..
150:1-2.
2018
-
The impact of health insurance status on the stage of cervical cancer diagnosis at a tertiary care center in Massachusetts..
150:67-72.
2018
-
Estimating potential for savings for low risk endometrial cancer using the Endometrial Cancer Alternative Payment Model (ECAP): A companion paper to the Society of Gynecologic Oncology Report on the Endometrial Cancer Alternative Payment Model..
149:241-247.
2018
-
Society of Gynecologic Oncology Future of Physician Payment Reform Task Force report: The Endometrial Cancer Alternative Payment Model (ECAP)..
149:232-240.
2018
-
Impact of age at diagnosis on racial disparities in endometrial cancer patients..
149:12-21.
2018
-
Urinary diversion in the genitourinary cancer survivor..
148:414-421.
2018
-
The use of patient-reported outcome tools in Gynecologic Oncology research, clinical practice, and value-based care..
148:12-18.
2018
-
Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group study..
147:648-653.
2017
-
Surgical readmission and survival in women with ovarian cancer: Are short-term quality metrics incentivizing decreased long-term survival?.
147:607-611.
2017
-
Use of a novel sentinel lymph node mapping algorithm reduces the need for pelvic lymphadenectomy in low-grade endometrial cancer..
147:535-540.
2017
-
An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience..
147:243-249.
2017
-
Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study..
147:396-401.
2017
-
Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?.
147:85-91.
2017
-
Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study..
147:98-103.
2017
-
A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study..
146:554-559.
2017
-
Insurance coverage among women diagnosed with a gynecologic malignancy before and after implementation of the Affordable Care Act..
146:457-464.
2017
-
The costs of adding laparoscopy to the management of advanced stage epithelial ovarian cancer..
146:441-442.
2017
-
Cost-effectiveness of opportunistic salpingectomy for ovarian cancer prevention..
146:373-379.
2017
-
Sentinel lymph node mapping and staging in endometrial cancer: A Society of Gynecologic Oncology literature review with consensus recommendations..
146:405-415.
2017
-
Frequency of "incidental" serous tubal intraepithelial carcinoma (STIC) in women without a history of or genetic risk factor for high-grade serous carcinoma: A six-year study..
146:69-73.
2017
-
Mortality reduction and cost-effectiveness of performing hysterectomy at the time of risk-reducing salpingo-oophorectomy for prophylaxis against serous/serous-like uterine cancers in BRCA1 mutation carriers..
145:549-554.
2017
-
Variation in neoadjuvant chemotherapy utilization for epithelial ovarian cancer at high volume hospitals in the United States and associated survival..
145:500-507.
2017
-
Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial..
145:340-345.
2017
-
The "value" of value in gynecologic oncology practice in the United States: Society of Gynecologic Oncology evidence-based review and recommendations..
145:185-191.
2017
-
Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study..
144:459-467.
2017
-
Prior breast cancer and tamoxifen exposure does not influence outcomes in women with uterine papillary serous carcinoma..
144:531-535.
2017
-
Pre-diagnosis health-related quality of life, surgery, and survival in women with advanced epithelial ovarian cancer: A SEER-MHOS study..
144:348-353.
2017
-
Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?.
144:125-129.
2017
-
Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study..
143:484-489.
2016
-
Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis..
143:294-301.
2016
-
Stress and burnout among gynecologic oncologists: A Society of Gynecologic Oncology Evidence-based Review and Recommendations..
143:421-427.
2016
-
Lymphovascular space invasion in uterine corpus cancer: What is its prognostic significance in the absence of lymph node metastases?.
142:278-282.
2016
-
A personalized paradigm in the treatment of platinum-resistant ovarian cancer - A cost utility analysis of genomic-based versus cytotoxic therapy..
142:144-149.
2016
-
The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type..
141:454-460.
2016
-
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer..
141:386-401.
2016
-
Body mass index and mortality in endometrial cancer: A systematic review and meta-analysis..
140:184-190.
2016
-
Cognitive function during and six months following chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: An NRG oncology/gynecologic oncology group study..
139:541-545.
2015
-
Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients..
139:413-418.
2015
-
A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma..
139:275-282.
2015
-
Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma..
139:23-29.
2015
-
Bariatric surgery as a means to decrease mortality in women with type I endometrial cancer - An intriguing option in a population at risk for dying of complications of metabolic syndrome..
138:597-602.
2015
-
Consensus in controversy: The modified Delphi method applied to Gynecologic Oncology practice..
138:712-716.
2015
-
Improving NCCN guideline-adherent care for ovarian cancer: Value of an intervention..
138:694-699.
2015
-
Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis..
138:267-271.
2015
-
Patient and physician factors associated with participation in cervical and uterine cancer trials: an NRG/GOG247 study..
138:101-108.
2015
-
Selective cardiac surveillance in patients with gynecologic cancer undergoing treatment with pegylated liposomal doxorubicin (PLD)..
137:503-507.
2015
-
Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study..
136:542-548.
2015
-
A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer..
136:293-299.
2015
-
Lymphatic mapping and sentinel lymph node dissection compared to complete lymphadenectomy in the management of early-stage vulvar cancer: A cost-utility analysis..
136:300-304.
2015
-
Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: is it cost-effective?.
136:43-47.
2015
-
Invasion of uterine cervical squamous cell carcinoma cells is facilitated by locoregional interaction with cancer-associated fibroblasts via activating transforming growth factor-beta..
136:104-111.
2015
-
Methods, safety, and early clinical outcomes of dose escalation using simultaneous integrated and sequential boosts in patients with locally advanced gynecologic malignancies..
135:239-243.
2014
-
The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer..
135:349-358.
2014
-
SGO guidance document for clinical trial designs in ovarian cancer: a changing paradigm..
135:3-7.
2014
-
Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer..
133:446-453.
2014
-
Relationship between minimally invasive hysterectomy, pelvic cytology, and lymph vascular space invasion: a single institution study of 458 patients..
133:211-215.
2014
-
The complex triad of obesity, diabetes and race in Type I and II endometrial cancers: prevalence and prognostic significance..
133:28-32.
2014
-
A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study..
132:526-530.
2014
-
A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube..
132:517-525.
2014
-
A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy..
132:531-536.
2014
-
Cost of care using prophylactic negative pressure wound vacuum on closed laparotomy incisions..
132:684-689.
2014
-
Metformin is associated with improved survival in endometrial cancer..
132:438-442.
2014
-
Palliative services enhance the quality and value of gynecologic cancer care..
132:1-2.
2014
-
Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma?.
131:629-633.
2013
-
Genetic profiling to predict recurrence of early cervical cancer..
131:650-654.
2013
-
ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas..
131:8-14.
2013
-
How much is another randomized trial of lymph node dissection in endometrial cancer worth? A value of information analysis..
131:140-146.
2013
-
Palliative and hospice care in gynecologic cancer: a review..
131:215-221.
2013
-
Cost analysis of colposcopy for abnormal cytology in post-treatment surveillance for cervical cancer..
130:421-425.
2013
-
Cost-effectiveness of early palliative care intervention in recurrent platinum-resistant ovarian cancer..
130:426-430.
2013
-
Are supportive care-based treatment strategies preferable to standard chemotherapy in recurrent cervical cancer?.
130:317-322.
2013
-
A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy..
130:19-24.
2013
-
Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer..
130:64-68.
2013
-
Timing of end-of-life care discussion with performance on end-of-life quality indicators in ovarian cancer..
130:156-161.
2013
-
Transcript expression in endometrial cancers from Black and White patients..
130:169-173.
2013
-
Summary of the 44th Annual Meeting on Women's Cancers..
129:273-276.
2013
-
Global ovarian cancer health disparities..
129:258-264.
2013
-
Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer..
129:74-80.
2013
-
Validation of ovarian cancer gene expression signatures for survival and subtype in formalin fixed paraffin embedded tissues..
129:159-164.
2013
-
Vitamin D receptor (VDR) polymorphisms and risk of ovarian cancer in Caucasian and African American women..
129:173-178.
2013
-
We need a new paradigm in gynecologic cancer care: SGO proposes solutions for delivery, quality and reimbursement policies..
129:3-4.
2013
-
Comparison of methods to estimate health state utilities for ovarian cancer using quality of life data: a Gynecologic Oncology Group study..
128:175-180.
2013
-
Is bilateral lymphadenectomy for midline squamous carcinoma of the vulva always necessary? An analysis from Gynecologic Oncology Group (GOG) 173..
128:155-159.
2013
-
A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer..
128:65-70.
2013
-
Beyond mere obesity: effect of increasing obesity classifications on hysterectomy outcomes for uterine cancer/hyperplasia..
127:326-331.
2012
-
Cost effectiveness of concurrent gemcitabine and cisplatin with radiation followed by adjuvant gemcitabine and cisplatin in patients with stages IIB to IVA carcinoma of the cervix..
127:267-272.
2012
-
A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma..
127:22-26.
2012
-
DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination..
127:241-248.
2012
-
Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: a Gynecologic Oncology Group Study..
126:424-427.
2012
-
Physical strain and urgent need for ergonomic training among gynecologic oncologists who perform minimally invasive surgery..
126:437-442.
2012
-
Minimally invasive surgery versus laparotomy in women with high grade endometrial cancer: a multi-site study performed at high volume cancer centers..
126:180-185.
2012
-
Obesity: Too big a problem to ignore..
126:274-276.
2012
-
Surgical staging for endometrial cancer in the elderly - is there a role for lymphadenectomy?.
126:12-15.
2012
-
Economic impact of paclitaxel shortage in patients with newly diagnosed ovarian cancer..
125:631-634.
2012
-
Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer..
125:625-630.
2012
-
Keratosis reduces sensitivity of anal cytology in detecting anal intraepithelial neoplasia..
124:292-295.
2012
-
Robotic-assisted surgery in gynecologic oncology: a Society of Gynecologic Oncology consensus statement. Developed by the Society of Gynecologic Oncology's Clinical Practice Robotics Task Force..
124:180-184.
2012
-
Primary radiation therapy for medically inoperable patients with clinical stage I and II endometrial carcinoma..
124:36-41.
2012
-
Robotically assisted fluorescence-guided lymph node mapping with ICG for gynecologic malignancies: a feasibility study..
124:78-82.
2012
-
Health-related quality of life outcomes of docetaxel/carboplatin combination therapy vs. sequential therapy with docetaxel then carboplatin in patients with relapsed, platinum-sensitive ovarian cancer: results from a randomized clinical trial..
123:505-510.
2011
-
Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer..
123:581-587.
2011
-
The regulation of MASPIN expression in epithelial ovarian cancer: association with p53 status, and MASPIN promoter methylation: a gynecologic oncology group study..
123:314-319.
2011
-
Work related stress among gynecologic oncologists..
123:365-369.
2011
-
Retrospective review of an intraoperative algorithm to predict lymph node metastasis in low-grade endometrial adenocarcinoma..
123:65-70.
2011
-
Cost comparison of strategies for the management of venous thromboembolic event risk following laparotomy for ovarian cancer..
122:467-472.
2011
-
Proteomic analysis of stage I endometrial cancer tissue: identification of proteins associated with oxidative processes and inflammation..
121:586-594.
2011
-
Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells..
121:187-192.
2011
-
Prevention and early detection of cancer..
121:1.
2011
-
Endometrial cancer..
120:165-166.
2011
-
Single-port risk-reducing salpingo-oophorectomy with and without hysterectomy: surgical outcomes and learning curve analysis..
119:43-47.
2010
-
A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a gynecologic oncology group study..
118:139-144.
2010
-
Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype..
116:556-562.
2010
-
Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: an analysis of clinical outcomes and patterns of recurrence..
116:10-14.
2010
-
Association between the N-terminally truncated (DeltaN) p63alpha (DeltaNp63alpha) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group study..
115:424-429.
2009
-
A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study..
115:285-289.
2009
-
An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC)..
115:244-248.
2009
-
A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer..
114:442-447.
2009
-
Multicenter analysis of recurrence and survival in stage IIIA endometrial cancer..
114:279-283.
2009
-
Polymorphisms in TCEAL7 and risk of epithelial ovarian cancer..
114:260-264.
2009
-
The impact of human papillomavirus vaccination on cervical cancer prevention efforts..
114:360-364.
2009
-
Microarray analysis of gene expression in gynecologic cancers--still only the beginning..
114:1-2.
2009
-
Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment..
113:216-220.
2009
-
Cost effectiveness of a test to detect metastases for endometrial cancer..
112:526-530.
2009
-
Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study..
112:469-474.
2009
-
Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes..
112:558-562.
2009
-
The role of lymphadenectomy in the management of preoperative grade 1 endometrial carcinoma..
112:511-516.
2009
-
Relationship between tamoxifen use and high risk endometrial cancer histologic types..
112:150-154.
2009
-
A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study..
111:455-460.
2008
-
Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it?.
111:179-187.
2008
-
Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence..
110:374-382.
2008
-
Scientific innovation--pathway to progress in women's cancer..
109:316-322.
2008
-
The current and future role of screening in the era of HPV vaccination..
109:S31-S39.
2008
-
Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study..
108:493-499.
2008
-
Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer..
107:526-531.
2007
-
Primary surgery versus chemoradiation in the treatment of IB2 cervical carcinoma: a cost effectiveness analysis..
107:532-540.
2007
-
Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis..
107:211-218.
2007
-
Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions..
107:159-162.
2007
-
The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer..
107:285-291.
2007
-
Letter to the editor..
76:142-143.
2000
-
Cytokine use and survival in the first-line treatment of ovarian cancer: a Gynecologic Oncology Group Study.
2012